Collegium Pharmaceutical, Inc. (COLL) Gross Margin
- Gross margin · 12 months: Value 60.02%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 60.02% | Gross profit / revenue. Period ending 2026-06-30. $485.09M ÷ $808.21M × 100 ≈ 60.02% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 485.09M USD | Gross Profit |
| Revenue | 808.21M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 323.12M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $485.09M | $808.21M | $323.12M | 60.02% |
| 2026-03-31 | $483.18M | $796.33M | $313.15M | 60.68% |
| 2025-12-31 | $463.26M | $780.57M | $317.31M | 59.35% |
| 2025-09-30 | $433.17M | $757.07M | $323.90M | 57.22% |
| 2025-06-30 | $400.79M | $707.01M | $306.22M | 56.69% |
| 2025-03-31 | $383.21M | $664.28M | $281.07M | 57.69% |
| 2024-12-31 | $377.34M | $631.45M | $254.10M | 59.76% |
| 2024-09-30 | $373.69M | $599.25M | $225.56M | 62.36% |
| 2024-06-30 | $357.20M | $576.65M | $219.45M | 61.94% |
| 2024-03-31 | $340.22M | $566.92M | $226.70M | 60.01% |
| 2023-12-31 | $326.17M | $566.77M | $240.60M | 57.55% |
| 2023-09-30 | $281.33M | $546.64M | $265.31M | 51.46% |
| 2023-06-30 | $259.86M | $536.95M | $277.09M | 48.40% |
| 2023-03-31 | $238.39M | $524.95M | $286.56M | 45.41% |
| 2022-12-31 | $209.49M | $463.93M | $254.44M | 45.15% |
| 2022-09-30 | $158.37M | $361.68M | $203.31M | 43.79% |
| 2022-06-30 | $145.64M | $313.50M | $167.87M | 46.46% |
| 2022-03-31 | $143.51M | $272.90M | $129.38M | 52.59% |
| 2021-12-31 | $150.62M | $276.87M | $126.25M | 54.40% |
| 2021-09-30 | $196.24M | $325.78M | $129.53M | 60.24% |
| 2021-06-30 | $198.32M | $326.11M | $127.79M | 60.81% |
| 2021-03-31 | $196.45M | $321.23M | $124.78M | 61.16% |
| 2020-12-31 | $179.84M | $310.02M | $130.18M | 58.01% |
| 2020-09-30 | (m) | $307.95M | $147.29M | (m) |
| 2020-06-30 | (m) | $301.71M | $163.06M | (m) |
| 2020-03-31 | (m) | $298.70M | $182.02M | (m) |
| 2019-12-31 | (m) | $296.70M | $193.66M | (m) |
| 2019-09-30 | (m) | $295.93M | $174.30M | (m) |
| 2019-06-30 | (m) | $293.16M | $173.55M | (m) |
| 2019-03-31 | (m) | $291.18M | $171.74M | (m) |
| 2018-12-31 | (m) | $280.41M | $165.68M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $28.48M | $2.60M | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.71M | $213.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |